Jefferies Group LLC set a $36.00 target price on Aclaris Therapeutics Inc (NASDAQ:ACRS) in a research report sent to investors on Thursday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other analysts have also weighed in on ACRS. Guggenheim restated a buy rating and issued a $40.00 target price on shares of Aclaris Therapeutics in a research report on Thursday, April 6th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a hold rating to a buy rating and set a $35.00 target price on the stock in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $36.25.
Aclaris Therapeutics (NASDAQ:ACRS) opened at 30.03 on Thursday. Aclaris Therapeutics has a 12-month low of $16.86 and a 12-month high of $33.25. The company’s market cap is $783.42 million. The firm’s 50-day moving average price is $30.97 and its 200-day moving average price is $27.70.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.10. Equities research analysts forecast that Aclaris Therapeutics will post ($3.11) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2491723/jefferies-group-llc-analysts-give-aclaris-therapeutics-inc-acrs-a-36-00-price-target-2.html.
In other news, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total transaction of $13,098,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 46.40% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $4,739,000. Russell Investments Group Ltd. acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $1,413,000. Alyeska Investment Group L.P. acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $2,656,000. Rock Springs Capital Management LP raised its position in shares of Aclaris Therapeutics by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 1,016,000 shares of the biotechnology company’s stock worth $26,020,000 after buying an additional 16,000 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $209,000. Institutional investors own 61.94% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.